Contacts

Investment projects and startups in Ukraine

Investment Opportunity in a Biotech Company Developing Cancer-Fighting Therapeutic Viruses

Investment opportunity in a US-based company engineering proprietary viruses designed to identify and destroy cancerous tumors while sparing healthy cells. Its first drug candidate targets a rare form of liver cancer in children

Location
USA
Sector
Innovation and high technology
Business activity
Biotechnology
Stage
Startup
Type of investment
Equity
Required investments
$5 000

ID: 44893

06.11.26

A venture capital investment opportunity in a company preparing for its first clinical trials in humans. ICLUB and TA Ventures have been investing in the company since 2022, making this a follow-on investment in a business whose progress we have monitored for several years. The Series A round will fund the company through the generation of its first clinical data in patients — a milestone expected to have the greatest impact on its valuation.

Geographic focus of the project: United States (clinical trials in Boston in collaboration with Dana-Farber Cancer Institute and Boston Children's Hospital), followed by expansion into global markets through partnerships with major pharmaceutical companies.

Problem Statement

Most existing cancer treatments still damage healthy cells alongside cancerous tissue:

  • Chemotherapy and radiation therapy are effective but cause severe side effects, particularly in children.

  • The concept of treating cancer with viruses is not new: two such therapies have already been approved in the United States. However, most of the more than 100 clinical trials conducted in humans have failed.

  • Naturally occurring viruses are difficult to control: they act slowly, and the human immune system often eliminates most of the administered dose before it reaches the tumor (most people already have immunity to certain viruses, such as adenoviruses).

  • Competitors develop each new drug from scratch for a specific disease, meaning that every subsequent drug requires approximately the same time and investment as the first.

The company's initial target is hepatoblastoma, a rare form of liver cancer in children. First-line treatment is relatively effective, but when the cancer recurs, there are no effective treatment options, and nearly all such patients die within a year.

Solution and Product

Rather than modifying an existing virus, the team designs its own virus from scratch, much like engineers design a component using computer software.

  • "Two-factor authentication" for the virus: The virus can enter only cells exhibiting a specific cancer marker and begins replicating only when it detects a second marker within the cell. Additional molecular "off switches" suppress viral activity in healthy tissues.

  • Safe and fast-acting virus: The platform is based on a virus that does not cause disease in humans. It acts significantly faster than viruses used by competitors, and because patients have never been exposed to it, their immune systems do not eliminate it before it reaches the tumor.

  • AI-enabled platform: The process from computer-based design to a laboratory-validated virus takes weeks rather than months. The success rate of viral assembly is approximately 10 times higher than the average reported in published studies.

  • Single-dose treatment: Patients receive a single injection. The anticipated response involves several days of flu-like symptoms while the virus destroys the tumor.

Brief Market Overview

  • The global oncolytic virus market is estimated at approximately $222 million in 2025, with projected annual growth of around 15%, representing an almost fourfold increase by 2034.

  • The liver cancer therapeutics market was valued at approximately $3.8 billion in 2024, with projected annual growth exceeding 18%.

  • Major pharmaceutical companies regularly acquire promising oncology businesses before their drugs receive regulatory approval. For example, Merck paid approximately $394 million for a comparable company based solely on early-stage results.

  • Comparable companies that have advanced to human clinical trials are valued at approximately 10 times the company's current valuation, while a comparable company with an approved drug is valued at approximately 45 times more.

  • Potential acquirers and partners: Major pharmaceutical companies developing oncology treatments.

Tangible and Intangible Assets

The company's primary asset is not a single drug but a technology platform that enables the rapid development of new therapies:

  • Cancer-targeting library: Since 2022, the number of validated combinations for targeting cancer cells has increased approximately sixfold and now covers numerous cancer types.

  • Proprietary laboratory data for AI: More than 100 engineered and tested viruses, supported by detailed experimental results. The company uses these datasets to train proprietary AI models unavailable to competitors.

  • Special FDA designations: The lead drug candidate has received Orphan Drug and Rare Pediatric Disease designations. These provide for seven years of market exclusivity, tax incentives for clinical trials, and the potential to obtain a Priority Review Voucher (PRV). Such vouchers can be sold to other pharmaceutical companies and have market values several times higher than the company's current valuation.

  • Established manufacturing capabilities: The first full-scale manufacturing run has been completed with partner Genezen. Production volume has increased more than 20-fold compared with laboratory-scale manufacturing without compromising quality.

  • Low production costs: The current manufacturing cost per dose is already several times lower than the price of Amgen's approved viral therapy and is expected to decline further as production scales.

  • Partnerships with leading oncology centers: Dana-Farber, Boston Children's Hospital, Memorial Sloan Kettering, and Yale.

Current Development Status and Achievements

The lead drug candidate has completed all key preclinical development stages:

  • Efficacy: In mouse studies, a single dose almost completely eliminated liver tumors, all animals survived, and their livers were healthy following treatment.

  • Safety: A dose more than 100,000 times higher than that required to destroy cancer cells is needed to affect healthy cells.

  • The FDA has agreed to the plan for the first human clinical trial and a streamlined toxicology testing pathway involving mice only.

  • Manufacturing: The full-scale manufacturing run has been completed. The next step is producing a clinical trial batch.

Additional drug candidates in development:

  • Adult liver cancer (in collaboration with Memorial Sloan Kettering): Positive laboratory results and the first successful animal study.

  • Pancreatic cancer (in collaboration with Yale): Development of the targeting mechanism is nearly complete.

  • Colorectal cancer: Also under development.

Investment Round and Financing:

  • The Series A round is co-led by Union Square Ventures, which also led the previous round, and MBX Capital. Together, they are contributing more than half of the total round.

  • The company has reached its current stage with highly disciplined capital allocation: the new financing round is nearly equal to the total capital raised in all previous years.

  • The company is close to signing its first agreement with charitable foundations to develop viruses targeting rare cancers using foundation funding. This could cover most of its operating expenses within a year.

  • Existing investors include Union Square Ventures, MBX Capital, Y Combinator, and TA Ventures.

Management Team and Personnel

  • Co-founder and CEO: A serial entrepreneur who founded and led a well-known technology company and successfully raised capital for three businesses. Holds a degree in engineering physics.

  • Co-founder and Chief Scientific Officer: A biotechnology specialist and inventor of the core technology that makes viruses programmable. Educated and professionally trained at leading US universities and medical centers.

  • Head of Manufacturing and Regulatory Affairs: Extensive experience at a major pharmaceutical company, having brought more than ten drugs to market.

  • Clinical Advisor: A pediatric oncologist at one of the leading US cancer centers who heads the liver tumor program within a major pediatric oncology research group. Will serve as the principal investigator for the first clinical trial.

  • Scientific Advisors: Leading experts in gene therapies and the viruses underlying the company's platform.

The team is small, and the company intends to maintain a lean organizational structure until the completion of its first clinical trial. Planned hires include a Head of Clinical Operations and a Chief Medical Officer.

Key Current and Target Project Metrics

Current Metrics:

  • A single dose almost completely eliminates tumors in mice, with all treated animals surviving.

  • Safety margin exceeding 100,000-fold between the dose required to kill cancer cells and the dose affecting healthy cells.

  • Cancer-targeting library expanded approximately sixfold since 2022.

  • Viral engineering success rate approximately 10 times higher than the industry average.

  • Manufacturing capacity increased more than 20-fold without compromising quality.

  • An in-house vivarium reduces the cost of mouse studies by a factor of four.

Target Metrics:

  • Submission of an Investigational New Drug (IND) application to the FDA — mid-2027.

  • First patients enrolled — late 2027.

  • Initial human clinical data — 2028.

  • AI-enabled development of targeting mechanisms for new cancer types several times faster and tens of times cheaper than currently possible.

  • Longer-term objective: Advance multiple therapeutic programs simultaneously and reduce the time from viral design to human clinical testing to less than one year.

Investment Offer

A venture capital investment model in which returns are generated exclusively through the appreciation of the company's valuation and the subsequent sale of ICLUB's equity stake, without dividend payments.

  • Minimum investment: $5,000; participation through a Special Purpose Vehicle (SPV); venture capital model with returns generated through capital appreciation.

  • Valuation: Series A investment at a valuation approximately 10 times lower than comparable companies that have already entered human clinical trials.

  • Deadline: November 13, 2026.

Potential Exit Opportunities

  • Most likely scenario: A transaction with a major pharmaceutical company following the first human clinical data (around 2028). This would initially involve licensing the drug, with a potential acquisition of the company if the second drug candidate also proves successful.

  • IPO: Considered realistic in 2030–2032, once clinical trial data become available.

  • Growth potential: Comparable companies at the human clinical trial stage are valued at approximately 10 times the company's current valuation, while a comparable company with an approved drug is valued at approximately 45 times more.

  • Additional value driver: If the drug is approved, the company may receive and sell an FDA Priority Review Voucher, which alone could be worth several times the company's current valuation.

  • Early investor liquidity: The CEO is also considering options for returning capital to investors before an acquisition or IPO, including share buybacks and distributions.

  • Additional funding: The company will most likely require another financing round after obtaining its initial clinical data.

Potential return multiple: Investors can enter before the first clinical data become available, at a valuation approximately 10 times lower than comparable companies already conducting human trials. However, this is an early-stage biotechnology investment, and the principal risk is that results in humans may differ from those observed in animal studies. The platform partially mitigates this risk by allowing the company to develop several drug candidates in parallel.

Additional information about the investment opportunity is available after registering on the platform via the link or QR code

Contacts

Connect with us!